Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy

doi:10.1016/j.ejca.2021.06.024

. 2021 Sep:154:190-200.

doi: 10.1016/j.ejca.2021.06.024. Epub 2021 Jul 19.

Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy

Angelina Tjokrowidjaja¹, Michael Friedlander², Sarah J Lord³, Rebecca Asher⁴, Manuel Rodrigues⁵, Jonathan A Ledermann⁶, Ursula A Matulonis⁷, Amit M Oza⁸, Ilan Bruchim⁹, Tomasz Huzarski¹⁰, Charlie Gourley¹¹, Philipp Harter¹², Ignace Vergote¹³, Clare L Scott¹⁴, Werner Meier¹⁵, Ronnie Shapira-Frommer¹⁶, Tsveta Milenkova¹⁷, Eric Pujade-Lauraine¹⁸, Val Gebski⁴, Chee K Lee¹⁹

Affiliations

¹ National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, NSW 2050, Australia; Department of Medical Oncology, St George Hospital, Kogarah, NSW 2217, Australia; Australia New Zealand Gynecological Oncology Group, Camperdown, New South Wales, Australia. Electronic address: angelina.tjokrowidjaja@sydney.edu.au.
² Australia New Zealand Gynecological Oncology Group, Camperdown, New South Wales, Australia; Department of Medical Oncology, Prince of Wales Hospital, Randwick, NSW 2031, Australia.
³ National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, NSW 2050, Australia; School of Medicine, The University of Notre Dame, Sydney, NSW 2007, Australia.
⁴ National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, NSW 2050, Australia.
⁵ INSERM U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisée Par La Ligue Nationale Contre le Cancer, Paris, France; Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France.
⁶ UCL Cancer Institute, University College London, London WC1E 6DD, Great Britain, UK.
⁷ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
⁸ Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2C1, Canada.
⁹ Gynecologic Oncology Division, Hillel Yaffe Medical Center, Technion Institute of Technology, Haifa, Israel.
¹⁰ Department of Genetics and Pathology, Pomeranian Medical University, 70-204 Szczecin, Poland.
¹¹ Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, MRC IGMM, University of Edinburgh, Western General Hospital, Edinburgh, UK.
¹² Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany.
¹³ Department of Oncology, KU Leuven - University of Leuven, B-3000 Leuven, Belgium; Division of Gynaecological Oncology, University Hospitals Leuven, B-3000 Leuven, Belgium.
¹⁴ Walter and Eliza Hall Institute of Medical Research, Stem Cells, and Cancer, University of Melbourne, Melbourne, Victoria, Australia.
¹⁵ Department of Gynaecology and Obstetrics, Evangelisches Krankenhaus Düsseldorf, Germany; University Hospital Düsseldorf, Düsseldorf, Germany.
¹⁶ Sheba Medical Center, Ramat-Gan, Israel.
¹⁷ AstraZeneca, Cambridge, United Kingdom.
¹⁸ Université Paris Descartes, Paris, France; ARCAGY-GINECO, Australia.
¹⁹ National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, NSW 2050, Australia; Department of Medical Oncology, St George Hospital, Kogarah, NSW 2217, Australia; Australia New Zealand Gynecological Oncology Group, Camperdown, New South Wales, Australia.

PMID: 34293664
DOI: 10.1016/j.ejca.2021.06.024

Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy

Angelina Tjokrowidjaja et al. Eur J Cancer. 2021 Sep.

. 2021 Sep:154:190-200.

doi: 10.1016/j.ejca.2021.06.024. Epub 2021 Jul 19.

Authors

Affiliations

¹ National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, NSW 2050, Australia; Department of Medical Oncology, St George Hospital, Kogarah, NSW 2217, Australia; Australia New Zealand Gynecological Oncology Group, Camperdown, New South Wales, Australia. Electronic address: angelina.tjokrowidjaja@sydney.edu.au.
² Australia New Zealand Gynecological Oncology Group, Camperdown, New South Wales, Australia; Department of Medical Oncology, Prince of Wales Hospital, Randwick, NSW 2031, Australia.
³ National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, NSW 2050, Australia; School of Medicine, The University of Notre Dame, Sydney, NSW 2007, Australia.
⁴ National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, NSW 2050, Australia.
⁵ INSERM U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisée Par La Ligue Nationale Contre le Cancer, Paris, France; Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France.
⁶ UCL Cancer Institute, University College London, London WC1E 6DD, Great Britain, UK.
⁷ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
⁸ Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2C1, Canada.
⁹ Gynecologic Oncology Division, Hillel Yaffe Medical Center, Technion Institute of Technology, Haifa, Israel.
¹⁰ Department of Genetics and Pathology, Pomeranian Medical University, 70-204 Szczecin, Poland.
¹¹ Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, MRC IGMM, University of Edinburgh, Western General Hospital, Edinburgh, UK.
¹² Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany.
¹³ Department of Oncology, KU Leuven - University of Leuven, B-3000 Leuven, Belgium; Division of Gynaecological Oncology, University Hospitals Leuven, B-3000 Leuven, Belgium.
¹⁴ Walter and Eliza Hall Institute of Medical Research, Stem Cells, and Cancer, University of Melbourne, Melbourne, Victoria, Australia.
¹⁵ Department of Gynaecology and Obstetrics, Evangelisches Krankenhaus Düsseldorf, Germany; University Hospital Düsseldorf, Düsseldorf, Germany.
¹⁶ Sheba Medical Center, Ramat-Gan, Israel.
¹⁷ AstraZeneca, Cambridge, United Kingdom.
¹⁸ Université Paris Descartes, Paris, France; ARCAGY-GINECO, Australia.
¹⁹ National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, NSW 2050, Australia; Department of Medical Oncology, St George Hospital, Kogarah, NSW 2217, Australia; Australia New Zealand Gynecological Oncology Group, Camperdown, New South Wales, Australia.

PMID: 34293664
DOI: 10.1016/j.ejca.2021.06.024

Abstract

Background: The impact of maintenance therapy with PARP inhibitors (PARPi) on progression-free survival (PFS) in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer (PSROC) varies widely. Individual prognostic factors do not reliably distinguish patients who progress early from those who have durable benefit. We developed and validated a prognostic nomogram to predict PFS in these patients.

Methods: The nomogram was developed using data from a training patient cohort with BRCA mutations and high-grade serous PSROC on the placebo arm of two maintenance therapy trials, Study 19 and SOLO2/ENGOT-ov21. We performed multivariable Cox regression analysis based on pre-treatment characteristics to develop a nomogram that predicts PFS. We assessed the discrimination and validation of the nomogram in independent validation patient cohorts treated with maintenance olaparib.

Results: The nomogram includes four PFS predictors: CA-125 at randomisation, platinum-free interval, presence of measurable disease and number of prior lines of platinum therapy. In the training (placebo) cohort (internal validation C-index 0.64), median PFS in the model-predicted good, intermediate and poor-risk groups was: 7.7 (95% CI 5.3-11.3), 5.4 (4.8-5.8) and 2.9 (2.8-4.4) months, respectively. In the validation (olaparib) cohort (C-index 0.71), median PFS in the model-predicted good, intermediate and poor-risk groups was: not reached, 16.6 (13.1-22.4) and 8.3 (7.1-10.8) months, respectively. The nomogram showed good calibration in the validation cohort (calibration plot).

Conclusions: This nomogram can be used to predict PFS and counsel patients with BRCA mutations and PSROC prior to maintenance olaparib and for stratification of patients in trials of maintenance therapies.

Keywords: BRCA mutation; Nomogram; Olaparib; Ovarian cancer; Poly(ADP-ribose) polymerase inhibitors; Prognosis.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement AT reports institutional research funding from AstraZeneca; travel and accommodation funding from AstraZeneca and Janssen. MF has received honoraria from AstraZeneca and GlaxoSmithKline; provided consulting or advisory role to AstraZeneca, Lilly, MSD, Novartis, GlaxoSmithKline and Takeda; reports institutional research funding from AstraZeneca, Novartis and BeiGene; travel and accommodation funding from AstraZeneca. MR has honoraria from AstraZeneca and GlaxoSmithKline; provided consulting or advisory role to AstraZeneca and GlaxoSmithKline; participated on a data safety monitoring board or advisory board for AstraZeneca and GlaxoSmithKline; received travel and accommodation funding from GlaxoSmithKline. JAL has received honoraria from AstraZeneca/MedImmune; provided a consulting or advisory role to Artios, AstraZeneca/MedImmune, Clovis Oncology, Cristal Therapeutics, Esai, Merck, Pfizer, Seattle Genetics and Tesaro; Speakers’ bureau for Clovis Oncology, Pfizer and Tesaro/GSK; reports institutional research funding from AstraZeneca, MSD Oncology; travel and accommodation funding from Clovis and discloses another relationship with Regeneron. UAM has provided a consulting or advisory role to Merck, Immunogen and Novartis; reports research funding from Merck, Novartis, Tesaro, Syndax, Immunogen, Mersana, Leap Therapeutics, Fujifilm, and SQZ Biotechnologies; travel and accommodation funding from AstraZeneca. AMO has received honoraria from Intas; provided a consulting or advisory role for Immunogen, Merck KGaA; reports institutional research funding from AstraZeneca, Immunovaccine; travel and accommodation funding from AstraZeneca; and discloses other relationships with AstraZeneca, Clovis Oncology, Merck and Tesaro. CG has received honoraria from Roche/Genentech, provided a consulting or advisory role for AstraZeneca; Speakers’ bureau for AstraZeneca; reports research funding from AstraZeneca. PH has received honoraria from AstraZeneca; provided a consulting or advisory role for AstraZeneca; reports institutional research funding from AstraZeneca; travel and accommodation funding from AstraZeneca. IV has provided consulting or advisory role to Amgen Europe, AstraZeneca, Carrick Therapeutics, Clovis Oncology, Debiopharm Group, F. Hoffmann La Roche, Genmab, GSK Pharmaceuticals, Immunogen, Medical University of Vienna, Millennium, MSD Belgium, Octimet Oncology, Oncoinvent, PharmaMar, Roche, Sotio and Tesaro; reports institutional research funding from Amgen, Genmab, Oncoinvent, Roche; travel and accommodation funding from Amgen, AstraZeneca, MSD, Merck, Roche and Tesaro. CLS reports research funding from Roche, Genentech, Clovis Oncology, Sierra Oncology, and Eisai; travel and accommodation funding from AstraZeneca; other relationship with Clovis Oncology. RSF has received honoraria from MSD Oncology, Bristol-Myers Squibb, Novartis, Roche, and AstraZeneca; provided a consulting or advisory role for VBL Therapeutics, Clovis Oncology; travel and accommodation funding from Bristol-Meyers Squibb, MSD Oncology, AstraZeneca. TM discloses employment and stockholder interests with AstraZeneca. EPL has received honoraria from AstraZeneca, GSK, Tesaro; provided consulting or advisory role to AstraZeneca, Clovis Oncology, Incyte, Merck, Pfizer/EMD, Serono, Roche, Tesaro; travel and accommodation funding from AstraZeneca, Roche, Tesaro and discloses other relationship with ARCAGY RESEARCH. CKL has received honoraria from AstraZeneca, Novartis, Pfizer, Roche and Boehringer Ingelheim; research funding from AstraZeneca; provided a consulting or advisory role to AstraZeneca, Novartis, Pfizer, Boehringer Ingelheim; received travel and accommodation funding from AstraZeneca and Boehringer Ingelheim. All remaining authors have declared no conflicts of interest.

Cited by

The Efficacy of Platinum Chemotherapy in a Japanese Malignant Melanoma Patient With a BRCA2 Mutation Identified by Gene Panel Testing.
Takayanagi-Hara R, Saito-Sasaki N, Okada E, Sawada Y. Takayanagi-Hara R, et al. Cureus. 2023 Sep 19;15(9):e45572. doi: 10.7759/cureus.45572. eCollection 2023 Sep. Cureus. 2023. PMID: 37868454 Free PMC article.
Differences of survival benefits brought by various treatments in ovarian cancer patients with different tumor stages.
He T, Li H, Zhang Z. He T, et al. J Ovarian Res. 2023 May 11;16(1):92. doi: 10.1186/s13048-023-01173-7. J Ovarian Res. 2023. PMID: 37170143 Free PMC article.
What predicts the clinical benefits of PARP inhibitors in platinum-sensitive recurrent ovarian cancer: A real-world single-center retrospective cohort study from China.
Zhang D, Li S, Zhang X, Peng J, Zhang S. Zhang D, et al. Front Oncol. 2022 Aug 18;12:955124. doi: 10.3389/fonc.2022.955124. eCollection 2022. Front Oncol. 2022. PMID: 36059631 Free PMC article.
Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives.
Quesada S, Fabbro M, Solassol J. Quesada S, et al. Cancers (Basel). 2022 Feb 21;14(4):1098. doi: 10.3390/cancers14041098. Cancers (Basel). 2022. PMID: 35205846 Free PMC article. Review.
Conditional Survival of Advanced Epithelial Ovarian Cancer: A Real-World Data Retrospective Cohort Study From the SEER Database.
Zheng P, Zheng P, Chen G. Zheng P, et al. Front Med (Lausanne). 2021 Nov 23;8:756401. doi: 10.3389/fmed.2021.756401. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34888325 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- Genetic Alliance
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy

Affiliations

Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous

Abstract

Conflict of interest statement

Similar articles

Cited by

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous